Cervical cancer clinical trials

Seattle Cancer Care Alliance (SCCA) was formed, in part, to bring promising new treatments to patients faster. For cervical cancer patients, this means more treatment options at SCCA than you might find elsewhere, including the chance to participate in one of many ongoing clinical trials conducted at SCCA and its partner organizations, Fred Hutch and UW Medicine.

Below is a list of cervical cancer clinical trials that are currently open and accepting patients at SCCA.
For general information about clinical trials, see the Patient Guide to Clinical Trials.

Displaying 5 of 5 trials

Start new search

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

Investigator:

John B. Liao, MD, PhD

Study ID:

NCT03635567

View Trial

A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358)

Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-963558) In subjects with Virus-Positive and Virus-Negative Tumors

Investigator:

Shailender Bhatia, MD

Study ID:

NCT02488759

View Trial

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Investigator:

Heidi J. Gray, MD

Study ID:

NCT00980954

View Trial

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Clinical Trial: A Randomized, Double-Blind, Placebo-Controlled Trial

Investigator:

Anna Wald, MD, MPH

Study ID:

NCT03051516

View Trial